About Oscine Therapeutics
Oscine Therapeutics is a Healthcare company based in New York (United States) founded in 2017, and was acquired by Sana Biotechnology in November 2020. Stem cell-based therapeutics are developed for CNS diseases. Its chief executive, as recorded, is Christina Trojel Hansen. Oscine Therapeutics offers products and services including Engineered Cell Therapies and Drug Candidates. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Oscine Therapeutics was founded in 2017 in New York, United States, within the biotechnology sector. Stem cell-based therapeutics are developed by the company to address neurological diseases. A platform has been created to produce biopotential astrocyte-oligodendrocyte glial progenitor cells for degenerative conditions. The pipeline encompasses treatments for Pelizaeus-Merzbacher disease and secondary progressive multiple sclerosis, both in IND-toxicology stages, alongside preclinical efforts for Huntingtons disease.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website oscinetherapeutics.com
- Social LinkedIn
- Acquired by Sana Biotechnology (Nov 2020)
- Investors
- Acquired bySana Biotechnology
(Nov 2020)
Products & Services of Oscine Therapeutics
Oscine Therapeutics offers a comprehensive portfolio of products and services, including Engineered Cell Therapies and Drug Candidates.
Repairs genes in cells to treat diseases like cancer
Advances treatments for diabetes and autoimmune disorders
Investors in Oscine Therapeutics
Oscine Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sana Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | sana.com | Seattle, United States |
Investor details for Oscine Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oscine Therapeutics
1 people are tracked at Oscine Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christina Trojel Hansen | CEO | Leadership |
Complete people profiles for Oscine Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Oscine Therapeutics
2 dated milestones of Oscine Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Oscine Therapeutics is founded.
- Exit Acquired by Sana Biotechnology.
Competitors of Oscine Therapeutics
Oscine Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. |
Detailed competitors of Oscine Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Oscine Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Oscine Therapeutics
Oscine Therapeutics was founded in 2017.
Oscine Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Christina Trojel Hansen is the CEO of Oscine Therapeutics, as recorded in our data.
Oscine Therapeutics was founded in 2017 in New York, United States, within the biotechnology sector. Stem cell-based therapeutics are developed by the company to address neurological diseases. A platform has been created to produce biopotential astrocyte-oligodendrocyte glial progenitor cells for degenerative conditions. The pipeline encompasses treatments for Pelizaeus-Merzbacher disease and secondary progressive multiple sclerosis, both in IND-toxicology stages, alongside preclinical efforts for Huntingtons disease.
Oscine Therapeutics's top competitors include PTC Therapeutics, Neurocrine and Biohaven Pharmaceutical.
Oscine Therapeutics offers Engineered Cell Therapies and Drug Candidates.
Oscine Therapeutics has 1 investor. Key investors include Sana Biotechnology.
Yes. Oscine Therapeutics was acquired by Sana Biotechnology in November 2020.